Skip to content 
Biopharmaceuticals Contract Manufacturing Market Overview
According to Mordor Intelligence, the biopharmaceuticals contract manufacturing market size is estimated at USD 53.68 billion in 2026, growing from USD 47.42 billion in 2025 and projected to reach USD 99.84 billion by 2031, at a CAGR of 13.21% during the forecast period. This steady rise reflects how pharmaceutical companies are increasingly relying on external partners to manage complex manufacturing needs while focusing on core research and commercialization activities.
The biopharmaceuticals contract manufacturing industry is experiencing strong demand as biologics, biosimilars, and advanced therapies continue to dominate drug development pipelines. Companies are seeking specialized manufacturing expertise, flexible production capacity, and faster turnaround times, all of which are offered by contract development and manufacturing organizations. This shift is helping organizations manage costs while maintaining quality and compliance across global markets.
Key Trends in the Biopharmaceuticals Contract Manufacturing Market
Rising Preference for Outsourcing in the Biopharmaceuticals Contract Manufacturing Industry
Outsourcing has become a core strategy across the biopharmaceuticals contract manufacturing market. Pharmaceutical and biotech firms are choosing external manufacturing partners to reduce capital expenditure and access advanced production technologies. This trend is particularly visible among small and mid-sized companies that lack in-house manufacturing capabilities.
Expansion of Biologics and Biosimilars Driving Market Growth
The increasing focus on biologics and biosimilars is shaping the biopharmaceuticals contract manufacturing market trends. These therapies require specialized production environments and expertise, which encourages companies to partner with contract manufacturers. The growing acceptance of biosimilars across multiple regions is also contributing to the biopharmaceuticals contract manufacturing market share expansion.
Adoption of Single-Use Systems and Flexible Manufacturing
Single-use technologies are becoming widely adopted in the biopharmaceuticals contract manufacturing industry. These systems reduce contamination risks, improve efficiency, and allow quicker changeovers between production batches. As a result, contract manufacturers are able to offer more flexible and cost-effective solutions to clients.
Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/ja/industry-reports/biopharmaceuticals-contract-manufacturing-market?utm_source=emailwire
Biopharmaceuticals Contract Manufacturing Market Segmentation
By Product Type:
- Peptides and proteins
- Antibodies including monoclonal antibodies and antibody-drug conjugates
- Vaccines
- Biosimilars
- Other biologics
By Service Type:
- Process development
- cGMP drug substance manufacturing
- Fill-finish and lyophilization
- Analytical and quality control services
- Packaging and logistics
By Expression System:
- Mammalian systems
- Microbial systems
- Insect and plant systems
By Development Phase:
- Pre-clinical stage
- Early-stage clinical development
- Mid-stage clinical development
- Late-stage and commercial production
By Geography:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
Explore Our Full Library of Healthcare Research Report:
https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=emailwire
Biopharmaceuticals Contract Manufacturing Market Key Players and Competitive Landscape
The competitive landscape of the biopharmaceuticals contract manufacturing market is defined by global players with strong technical capabilities, extensive manufacturing networks, and broad service portfolios. These companies are focused on expanding capacity, improving efficiency, and strengthening client partnerships.
Key players in the biopharmaceuticals contract manufacturing market include:
- Boehringer Ingelheim GmbH
- Lonza Group
- Samsung Biologics
- WuXi Biologics
- Thermo Fisher Scientific Inc.
Conclusion
The future of the biopharmaceuticals contract manufacturing market remains positive as outsourcing continues to gain importance across the pharmaceutical value chain. The increasing complexity of biologics, combined with the need for efficient manufacturing processes, is expected to sustain demand for contract manufacturing services.
The biopharmaceuticals contract manufacturing market forecast indicates continued expansion supported by innovation in production technologies, rising biologics demand, and growing global collaboration. Companies that offer flexible, scalable, and high-quality manufacturing solutions are likely to strengthen their position in the market.
Overall, the biopharmaceuticals contract manufacturing industry is evolving in response to changing healthcare needs and industry dynamics. With a strong focus on efficiency, specialization, and global reach, the market is set to play a critical role in the development and delivery of next-generation therapies.
Get detailed insights on the biopharmaceuticals contract manufacturing market:
Industry Related Reports
Contract Research Organization Market:
The Contract Research Organization Market is witnessing growth driven by increasing outsourcing of clinical trials and rising demand for cost-effective drug development services. Growing pharmaceutical R&D activities are further supporting market expansion.
Get more insights: https://www.mordorintelligence.com/industry-reports/contract-research-organization-market?utm_source=emailwire
Oral Solid Dosage CDMO Market size:
The Oral Solid Dosage CDMO Market is projected to grow from USD 40.20 billion in 2025 to USD 57.18 billion by 2031, registering a CAGR of 6.17%. Growth is driven by increasing demand for outsourcing manufacturing services and rising production of oral drug formulations.
Get more insights: https://www.mordorintelligence.com/industry-reports/oral-solid-dosage-cdmo-market?utm_source=emailwire
Lipid Nanoparticle CDMO Market share:
The Lipid Nanoparticle CDMO Market was valued at USD 372.32 million in 2025 and is expected to reach USD 818.06 million by 2031, growing at a CAGR of 14.31%. Rising demand for mRNA-based therapeutics and advancements in drug delivery technologies are key drivers of market growth.
Get more insights: https://www.mordorintelligence.com/industry-reports/lipid-nanoparticle-cdmo-market?utm_source=emailwire
About Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries or to access the full report, please contact:
media@mordorintelligence.com
https://www.mordorintelligence.com/
